|
|
Article: OSI Pharmaceuticals IGF-1R Inhibitor Program Featured in 97th Annual Meeting of the American Association of Cancer Research Media Program.
- Article from:
- Business Wire
- Article date:
- April 5, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WASHINGTON -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that pre-clinical results from its insulin-like growth factor-1 receptor (IGF-1R) program were featured as part of a media program on molecular targeted therapies sponsored by the American Association of Cancer Research (AACR) during its annual meeting in Washington, DC held April 1-5, 2006. As highlighted in today's briefing, the research findings demonstrated that OSI's compound blocked the ability of IGF-1R to activate molecular signaling pathways within tumor cells, resulting in the inhibition of tumor growth. IGF-1R has been viewed as an important therapeutic target due to its involvement in the ...
Related newspaper, magazine, and journal articles:
|
|
Article: OSI Pharmaceuticals Summarizes Pre-Clinical Data ...
Business Wire;
April 19, 2005 ;
700+ words
...MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today ... growth factor-1 receptor (IGF-1R) as a model system to ... inhibiting lung cancer cell lines. IGF-1 is a growth factor, or ... data show that inhibition of IGF-1R enhances the degree of ...
|
|